Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2008-07-01
2008-07-01
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S311000, C514S312000, C514S313000, C514S314000, C514S922000
Reissue Patent
active
11222485
ABSTRACT:
This invention provides the use of a combination of CCI-779 and EKB-569 in the treatment of neoplasms.
REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4193983 (1980-03-01), Ullman et al.
patent: 4194050 (1980-03-01), Hazama
patent: 4195021 (1980-03-01), Herron et al.
patent: 4401653 (1983-08-01), Eng et al.
patent: 4478959 (1984-10-01), Bechara et al.
patent: 4565843 (1986-01-01), Dunwald
patent: 4576759 (1986-03-01), Viehe et al.
patent: 4664825 (1987-05-01), Walsh
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5066493 (1991-11-01), Sehgal et al.
patent: 5078999 (1992-01-01), Warner et al.
patent: 5080899 (1992-01-01), Sturm et al.
patent: 5100899 (1992-03-01), Calne et al.
patent: 5206018 (1993-04-01), Sehgal et al.
patent: 5286730 (1994-02-01), Caufield et al.
patent: 5286731 (1994-02-01), Caufield et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5321009 (1994-06-01), Baeder et al.
patent: 5352783 (1994-10-01), Shafiee et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5387589 (1995-02-01), Kulkarni et al.
patent: 5496832 (1996-03-01), Armstrong et al.
patent: 5516781 (1996-05-01), Morris et al.
patent: 5561138 (1996-10-01), Armstrong
patent: 6002008 (1999-12-01), Wissner et al.
patent: 6277983 (2001-08-01), Shaw et al.
patent: 6465448 (2002-10-01), Gerson et al.
patent: 6617333 (2003-09-01), Rabindran et al.
patent: 6664288 (2003-12-01), Pardee et al.
patent: 2004/0162442 (2004-08-01), Considine
patent: 0 448 078 (1991-09-01), None
patent: 0 525 960 (1996-03-01), None
patent: 0 722 720 (1996-07-01), None
patent: 0 525 960 (2003-02-01), None
patent: WO 02/13802 (2002-02-01), None
patent: WO 03/020266 (2003-03-01), None
patent: WO 2004/066919 (2004-08-01), None
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials”, British Journal of Cancer 84(10), 1424-1431 (2001).
Gura, Trisha, “Cancer Models: Systems for Identifying New Drugs are Often Faulty”, Science, vol. 278, No. 5340, pp. 1041-1042 (1997).
Balenovic, K. Contribution to the Knowledge of Gamma-Aminocrotonic Acid, J. Org. Chem. 19:1589-1593, (1954).
Wissner, Allan; et al, Synthesis and Structure-Activity relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-Carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2(HER-2);J. Med. Chem., 46:49-63, 2003.
Gupta, RA et al, Combinations for Cancer Prevention, Nature Medicine, 6(9), pp. 974-975, (Sep. 2000).
Torrance, C. et al, Combinatorial Chemoprevention of Intestinal Neoplasia, Nature medicine, 6(9), pp. 1024-1028, (Sep. 2000).
Greenberger, L.M.et al, Clinical Cancer Research, vol. 6, p. 38, (Nov. 2000).
Geoerger B, et al, Antitumor Activity of the Rapamycin Analog CCI-779 in Human Primitive Neuroectodermal .,Cancer Research , vol. 4, No. 61, pp. 1527-1532, (Feb. 15, 2001).
Vezina et al, Rapamycin (AY-22,989) A New Antifungal Antibiotic . . . , The Journal of Antibiotics, 28(10), 721-726, (Oct. 1975).
Sehgal et al, Rapamycin (AY-22,989) a New Antifungal Antibiotic, Fermentation, . . . , The Journal of Antibiotics, 28(10), 727-732, (Oct. 1975).
Baker et al, Rapamycin (AY-22,989), A New Antifungal Antibiotic, III. In vitro and In Vivo Evaluation,The Journal of Antibiotics, 31(6), 539-545, (Jun. 1978).
Calne et al, Prolonged Survival of Pig Orthotopic Heart Grafts Treated with Cyclosporin A, The Lancet, 1183-1185, (Jun. 1978).
Martel et al, Inhibition of the Immune Response by Rapamycin, a New Antifungal Antibiotic, Can. J. Physiol. Pharmacol. 55, 48-51, (1977).
Staruch et al, FK506 and Rapamycin Inhibit Murine T Cell Activation Through Different Mechanisms, The FASEB Journal, 3(3), (1989).
Dumont et al, Rapamycin Blocks The Immunosuppressive Effect of FK506 But Not that of Cyclosporin A, The FASEB Journal, 3(4), (1989).
Marszak I. et al., “Recherches Sur Les Aminoacides Et Leurs Derives. I.-Sur La Synthese Des Aminoacides A Partir Des Amines Tertiaires A Fonction Acetylenique Vrai Amino Acids and Their Derivatives. I. The Synthesis of Amino Acids from Tertiary Amnes Having a True Acetyl”, Bulletin de la Societe Chimique de France, Societe Francaise de Chimie, 1959, pp. 182-185.
European Search Report for European Patent Application No. 05019642.7.
“Novel Agent Appears Promising for Treatment of Some Cancers”, General Prostate Cancer News Archives, Prostate Cancer Research Institute, 2005.
E. Galanis et al, “Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study”, abstract from J. Clin Oncol., 23(23) (Aug. 10), 2005: pp. 5294.
B. Rubio-Viquera, et al, “Novel In Vivo Model for drug development in pancreas cancer”, J. Clin Oncol, 2005 ASCO Annual Meeting Proceedings, vol. 23, No. 16S, Part I of II (Jun. 1 Supplement), 2005:4098.
Witzig, et al, “Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma”,J Clin Oncol, 23:5347-56 (Aug. 10, 2005).
M. Hidalgo et al, CCI-779, a Rapamycin Analog and Multifaceted Inhibitor of Signal Transduction: a Phase I Study, abst 726, Proc Am Soc Clin Oncol (ASCO), vol. 19, 2000, p. 187a.
N. Yoshimura et al, “EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib”, Lung Cancer, 51(3):363-9 (Mar. 2006).
M. Hidalgo et al, “Phase 1 trial of EKB-569, an irreversible inhibitor of epidermal growth factor receptor (EGFR), in patients with advance solid tumors”, Proc Am Soc Clin Oncol, 21: 2002 (abstr 65).
Erlichman, et al., “Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients with Advance Solid Tumors”, J. Clin Oncol., 24 (15): May 20, 2006, pp. 2252-2260.
E. Raymond, et al., “CCI-779, A Rapamycin Analog with Antitumor Activity: A Phase I Study Utilizing a Weekly Schedule”, abst 728, Proc of ASCO, vol. 19(2000), p. 187a.
Gibbons, Jr. James J.
Rabindran Sridhar K.
Howson & Howson LLP
Krass Frederick
Milowsky Arnold S.
Wyeth
LandOfFree
Treatment of neoplasms with CCI-779/EKB-569 combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neoplasms with CCI-779/EKB-569 combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neoplasms with CCI-779/EKB-569 combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3938637